ACIPHEX

LOE Approaching

rabeprazole sodium

NDAOralTablet, Delayed Release
Approved
Nov 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8

Mechanism of Action

(substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H 2 -receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H, KATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as…

Clinical Trials (5)

NCT01241409Phase 1Completed

A Bioequivalence Study of 2 Formulations of Rabeprazole Sodium and Evaluation of the Effect of Food on Rabeprazole Sodium in Healthy Adult Volunteers

Started Oct 2010
78 enrolled
Healthy
NCT01202071Phase 2Completed

A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)

Started Sep 2010
24 enrolled
Healthy
NCT01186497Phase 1Completed

A Relative Bioavailability Study of Rabeprazole Sodium Administered With Different Dosing Vehicles in Healthy Adult Volunteers

Started Aug 2010
35 enrolled
Healthy
NCT01153659Phase 1Completed

A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets

Started Jul 2010
90 enrolled
Healthy
NCT01101646Phase 1Completed

A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers

Started Aug 2008
36 enrolled
Gastroesophageal Reflux